The Medicines Company  

(Public, NASDAQ:MDCO)   Watch this stock  
Find more results for MDCO
+0.10 (0.28%)
Aug 18 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 34.97 - 35.79
52 week 30.80 - 55.95
Open 35.40
Vol / Avg. 775,467.00/1.05M
Mkt cap 2.58B
P/E     -
Div/yield     -
EPS -9.96
Shares 72.64M
Beta 0.85
Inst. own 129%
Oct 24, 2017
Q3 2017 Medicines Co Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Aug 9, 2017
Q2 2017 Medicines Co Earnings Release
Aug 9, 2017
Q2 2017 Medicines Co Earnings Call - Webcast
May 26, 2017
Medicines Co Annual Shareholders Meeting (Estimated)
May 25, 2017
Medicines Co Annual Shareholders Meeting
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin -2119.67% -71.12%
Operating margin -2183.91% -218.85%
EBITD margin - -186.28%
Return on average assets -116.22% -6.82%
Return on average equity -405.35% -17.01%
Employees 410 -
CDP Score - -


United States - Map
+1-973-2906000 (Phone)
+1-973-6569898 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin). It also has a pipeline of products in development, including Carbavance, inclisiran and MDCO-700. Carbavance is used for the treatment of hospitalized patients with gram-negative bacterial infections. Inclisiran is used for the treatment of hypercholesterolemia. MDCO-700 includes sedative-hypnotic, which is used to induce and maintain sedation for procedural care and general anesthesia for surgical care. In addition to these products and products in development, it has a portfolio of generic drugs.

Officers and directors

Stuart A. Kingsley President, Chief Operating Officer
Age: 53
Bio & Compensation  - Reuters
Clive A. Meanwell M.D. Ph.D. Chief Executive Officer, Director
Age: 59
Bio & Compensation  - Reuters
William Bernard O'Connor Chief Financial Officer
Age: 58
Bio & Compensation  - Reuters
Christopher T. Cox Executive Vice President, Chief Corporate Development Officer
Age: 52
Bio & Compensation  - Reuters
Jeffrey Frazier Executive Vice President, Chief Human Strategy Officer
Age: 54
Bio & Compensation  - Reuters
Stephen M. Rodin J.D. General Counsel, Secretary
Age: 41
Bio & Compensation  - Reuters
Fredric N. Eshelman Pharm.D. Independent Non-Executive Chairman of the Board
Age: 68
Bio & Compensation  - Reuters
Paris Panayiotopoulos Director
Age: 43
Bio & Compensation  - Reuters
William W. Crouse Independent Director
Age: 74
Bio & Compensation  - Reuters
Alexander J. Denner Ph.D. Independent Director
Age: 47
Bio & Compensation  - Reuters